Test Price
750 AED✅ Home Collection Available
ROMA (Risk of Ovarian Malignancy Algorithm) Test in UAE | 750 AED | 2026 DHA Guidelines
تحليل مؤشر خطورة أورام المبيض (ROMA) في الإمارات | 750 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited laboratory processing (Cert: INT/EGQ/2509DA/3139). Dual-marker chemiluminescent immunoassay with menopausal status integration.
Premium Logistics: Paid Hospital‑Grade Home Collection available 8 AM–11 PM via ISO‑certified cold‑chain transport. VIP mobile phlebotomy ensures sample integrity from your doorstep to our DHA‑licensed facility (License: 9834453).
Clinical Guidance: Complimentary telephonic post‑test consultation with our specialist team to interpret ROMA results in the context of your imaging and clinical history.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We handle individual and corporate plans with full transparency under UAE PDPL.
نضمن دقة تشخيصية فائقة من خلال أحدث تقنيات الفحص المناعي الضوئي الكيميائي، مع خدمة سحب العينة منزلياً لتوفير أقصى درجات الراحة والخصوصية، وكل ذلك وفق أعلى معايير هيئة الصحة بدبي ووزارة الصحة ووقاية المجتمع.
Clinical Overview
The ROMA algorithm integrates serum CA125, HE4, and menopausal status to compute a personalized risk score for ovarian malignancy in women with an adnexal mass. This evidence‑based stratification supports timely referral to gynecologic oncology and reduces unnecessary surgeries.
يجمع تحليل ROMA بين دلالات الورم CA125 و HE4 وحالة انقطاع الطمث لحساب درجة خطورة الإصابة بسرطان المبيض لدى النساء اللواتي تظهر لديهن كتلة حوضية، مما يساعد الأطباء في اتخاذ قرارات علاجية مستنيرة.
| Parameter | Our ROMA Test | Standalone CA125 / HE4 Tests |
|---|---|---|
| Precision | Algorithmic combination with menopausal status; superior sensitivity & specificity | Single marker; reduced accuracy, especially in premenopausal patients |
| Methodology | Chemiluminescent Microparticle Immunoassay (CMIA) – automated, high‑throughput | Often ECLIA or ELISA; manual interpretation may vary |
| Turnaround Time | Same day (sample collection Mon/Thu before 4 PM) | 2–3 days typical |
| Pre‑analytical Guidance | Menopausal status mandatory; cold‑chain logistics included | Often no structured pre‑test counseling |
Physician Insight & Safety Protocol
“As a clinician, I understand the anxiety that comes with a pelvic mass. The ROMA test is a powerful tool for risk stratification, but it is not a substitute for a thorough clinical evaluation and imaging. Please use this result in conjunction with your gynecologist's or oncologist's expertise to decide on the best management pathway.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠ Medication Warning: Do not discontinue any prescribed medication without consulting your treating physician. Neither the ROMA score nor any single test should alter your current therapeutic regimen without professional supervision.
Exclusion Criteria & Emergency Red Flags
- Pregnancy or postpartum state (CA125 and HE4 levels are physiologically altered).
- Acute pelvic inflammatory disease or active endometriosis (may cause false‑positive elevations).
- Known benign ovarian cysts with classical ultrasound features (unless malignancy is suspected).
- Seek emergency care if you experience: sudden, severe abdominal‑pelvic pain, fever, vomiting, or signs of ovarian torsion — these require immediate medical attention and are unrelated to ROMA testing.
Patient FAQ & Clinical Guidance
Q1: What does the ROMA test measure?
A: ROMA test calculates ovarian malignancy probability by integrating CA125, HE4 blood levels with menopausal information. It provides a numerical score that classifies a woman as low or high risk for epithelial ovarian cancer, aiding in triage of pelvic masses. This dual‑marker approach outperforms CA125 alone, particularly in premenopausal patients.
يقوم تحليل ROMA بحساب احتمالية وجود ورم خبيث في المبيض من خلال دمج مستويات CA125 و HE4 مع معلومات عن حالة انقطاع الطمث.
Q2: Who should take the ROMA test?
A: Adnexal mass patients, both pre‑ and postmenopausal, should take the ROMA test for risk evaluation. It is recommended for any woman found to have a persistent ovarian cyst or complex mass on ultrasound, regardless of age, to guide referral to a gynecologic oncologist if needed.
يُنصح بإجراء فحص ROMA لأي مريضة تعاني من كتلة في المنطقة الملحقة سواء كانت في سن الإنجاب أو بعد انقطاع الطمث، وذلك لتقييم خطورة الإصابة بسرطان المبيض وتوجيه الإحالة إلى طبيب الأورام النسائية عند الحاجة.
Q3: How accurate is the ROMA test?
A: ROMA shows 90% sensitivity and 85% specificity in detecting ovarian malignancy in pelvic mass patients. Clinical validation studies, including those referenced in the 2026 DHA laboratory updates, confirm its reliability as a non‑invasive stratification tool. Sensitivity is highest in postmenopausal women, but the algorithm remains informative across all menopausal statuses.
يتمتع تحليل ROMA بحساسية تصل إلى 90% ونوعية 85% للكشف عن سرطان المبيض لدى مريضات الكتل الحوضية، وفقاً للدراسات السريرية المعتمدة.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians